

ASX ANNOUNCEMENT**ASX: 1AI** | 1 July 2026**Algorae Awarded NSW Health Public Hospital Supply Contract; Rollout Underway****Highlights**

- Algorae awarded a public hospital supply contract with NSW Health, following a competitive tender process.
- Initial contract term of three years, with two optional one-year extension periods (3+1+1 years).
- Onboarding and rollout underway, with first supply expected in Q4 2026.
- Contract terms, including pricing and volumes, are confidential under the agreement; revenue will be recognised within the Company's total product revenue.
- The award provides strong validation of Algorae's strategy and commercial execution, positioning the Company for further growth.

AI-enabled pharmaceutical company **Algorae Pharmaceuticals Ltd (ASX: 1AI)** ("Algorae" or "the Company") is pleased to announce it has been awarded a public hospital supply contract with NSW Health, following a competitive tender process.

Tender Award

Algorae has been selected as a supplier under a NSW Health public hospital supply contract for an initial term of three years, with two optional one-year extensions (3+1+1 years).

The terms of the agreement, including scope, pricing and volumes, are confidential, and the Company is therefore unable to quantify the financial impact of the award at this time. Revenue from the agreement will be recognised and reported within the Company's total product revenue. The Company will make further disclosures if and when the information becomes capable of disclosure, in line with its continuous disclosure obligations.

The Company regards the NSW Health supply contract as an important milestone in its commercial strategy. It will provide updates on future tender awards in its quarterly activities report.

Managing Director and Chief Commercial Officer of AlgoraeRx, **Mr Vishal Shah**, said:

"Securing a place on a NSW Health supply contract is a major milestone for AlgoraeRx. It validates the strength of our commercial capabilities and provides access to one of Australia's largest public healthcare procurement networks."

Outlook

Algorae will focus on supporting rollout and meeting its obligations under the contract, while continuing to pursue further public healthcare procurement opportunities. The Company will provide updates in line with its continuous disclosure obligations.

About Algorae Pharmaceuticals

Algorae Pharmaceuticals Ltd (ASX: 1AI) is an Australian AI-enabled pharmaceutical company pursuing a dual-track strategy that combines AI-driven drug discovery with pharmaceutical commercialisation.

Algorae's discovery business is built around AlgoraeOS, a proprietary AI platform that applies machine learning and deep neural networks to predict synergistic drug combinations. AlgoraeOS was developed in collaboration with the UNSW AI Institute, with support from CSIRO Data61. Its predictions have been independently validated by the Peter MacCallum Cancer Centre. The platform underpins a growing pipeline of AI-generated drug-combination candidates across oncology, neurodegenerative and other complex diseases.

Through its wholly owned commercial division, AlgoraeRx, the Company brings specialty and generic medicines to market across Australia and New Zealand under distribution and supply partnerships, building a revenue base that complements its longer-term discovery pipeline.

For more information visit www.algoraeapharma.com or follow @algoraeapharma on X or LinkedIn.

**Authorised for release by the Board of Directors of Algorae Pharmaceuticals Ltd
ENDS.**

Corporate and Media Enquiries

Mr David Hainsworth
Executive Chairman
E: investors@algoraeapharma.com

Forward-looking Statements

This document may contain forward-looking statements relating to Algorae Pharmaceuticals Ltd (ASX: 1AI) ("Algorae" or the "Company") and its business, financial position and strategy. Forward-looking statements can generally be identified by the use of words such as "anticipate", "believe", "expect", "estimate", "intend", "plan", "project", "forecast", "target", "aim", "potential", "may", "will", "could", "should", "seek", "on track", or similar expressions, or by discussions of strategy, plans, objectives, future events or intentions.

Forward-looking statements are based on the Company's current expectations, assumptions and beliefs as at the date of this document, and involve known and unknown risks, uncertainties and other factors, many of which are beyond the Company's control. These factors may cause the Company's actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements. Such factors include, among others: research and development outcomes; the development, performance and commercialisation of the Company's technology and product candidates; regulatory approvals, requirements and actions of the TGA, FDA and other regulatory authorities; the Company's ability to obtain, maintain and protect intellectual property; commercial, distribution and supply arrangements; competition; funding and access to capital; pricing and reimbursement pressures; counterparty and partnership risks; and general economic, market and operating conditions.

In particular, statements regarding the approval and commercialisation of the Company's product candidates are subject to additional risks and uncertainties, including: unexpected clinical trial results, including additional analysis of existing data and new clinical data; unexpected regulatory actions or delays, or government regulation generally; and the Company's ability to obtain or maintain patent or other proprietary intellectual property protection. There can be no assurance that any existing or future regulatory filings will satisfy the requirements of the TGA, FDA or other health authorities in respect of any product candidate, that any product candidate will be approved for sale in any market, or that any product candidate will reach any particular level of sales.

Forward-looking statements are not guarantees of future performance and should not be relied upon as such. Past performance is not an indicator or guarantee of future performance. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those anticipated, believed, estimated or expected. To the maximum extent permitted by law, the Company and its related bodies corporate, directors, officers, employees and advisers make no representation or warranty (express or implied) as to the accuracy, completeness or likelihood of fulfilment of any forward-looking statement, and disclaim any responsibility for their accuracy or completeness. Nothing in this document constitutes financial product, investment, legal or tax advice, nor an offer of securities or a recommendation to acquire or dispose of any securities.

Except as required by law or the ASX Listing Rules, the Company does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or developments, or otherwise.